Literature DB >> 10966984

Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles.

D J Cahill1, P G Wardle, C R Harlow, L P Hunt, M G Hull.   

Abstract

Data relating serum oestradiol concentration to follicle size in unstimulated cycles are lacking. We provide precise data on serum concentrations expected for any follicle diameter (FD) in the mid- to late follicular phase. Infertile women (n = 35) with apparently normal ovulatory cycles were studied in detail in 128 unstimulated monofollicular cycles leading to IVF. Using mathematical modelling to account for repeated cycles in the same woman, the relationship between serum oestradiol and FD was explored and reference ranges for serum oestradiol at individual FD were calculated. Serum oestradiol concentrations [number of patients, geometric mean, 95% confidence interval (CI)] at the onset of the LH surge were higher in 'fertilized' cycles (73, 1279, 1180-1378 pmol/l) compared with 'unfertilized' cycles (31, 1055, 929-1197 pmol/l, P: = 0.008) and 'no oocyte' cycles (24, 1064, 922-1227 pmol/l, P: = 0.03) respectively. In 'fertilized' cycles, oestradiol concentrations rose exponentially with FD and for each size of follicle the oestradiol distribution was skewed. Functional oocyte competence varied in apparently normal ovulatory cycles and was correlated with pre-ovulatory serum oestradiol but not FD. Serum oestradiol varies within wide limits for maturing follicles of any given diameter prior to the onset of the LH surge.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966984     DOI: 10.1093/humrep/15.9.1909

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

Review 1.  Maintaining fertility in young women with breast cancer.

Authors:  Melissa C Hulvat; Jacqueline S Jeruss
Journal:  Curr Treat Options Oncol       Date:  2009-12

2.  Oncofertility conundrum: discrepancy between anti-Mϋllerian hormone and mature oocyte yield in a peripubertal girl with Hodgkin lymphoma.

Authors:  D Garg; E B Johnstone; D B Fair; D T Carrell; S Berga; J M Letourneau
Journal:  J Assist Reprod Genet       Date:  2019-07-15       Impact factor: 3.412

Review 3.  Breast cancer: an update on treatment-related infertility.

Authors:  Erica Silvestris; Miriam Dellino; Paola Cafforio; Angelo Virgilio Paradiso; Gennaro Cormio; Stella D'Oronzo
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-31       Impact factor: 4.553

4.  Fertility preservation in women undergoing treatment for breast cancer in the UK: a questionnaire study.

Authors:  Judy W King; Melanie C Davies; Nicola Roche; Jacinta M Abraham; Alison L Jones
Journal:  Oncologist       Date:  2012-06-15

5.  Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?

Authors:  Imane Lalami; Julie Labrosse; Isabelle Cedrin-Durnerin; Marjorie Comtet; Claire Vinolas; Fabien Krief; Christophe Sifer; Maeliss Peigne; Michael Grynberg
Journal:  Reprod Biol Endocrinol       Date:  2022-06-11       Impact factor: 4.982

Review 6.  The Use of Estrone-3-Glucuronide and Pregnanediol-3-Glucuronide Excretion Rates to Navigate the Continuum of Ovarian Activity.

Authors:  Leonard F Blackwell; Delwyn G Cooke; Simon Brown
Journal:  Front Public Health       Date:  2018-05-31

7.  Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients.

Authors:  Charlotte Sonigo; Nathalie Sermondade; Jéremy Calvo; Julie Benard; Christophe Sifer; Michaël Grynberg
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-11

8.  Predictor for supraphysiologic serum estradiol elevation on hCG triggering day of controlled ovarian stimulation using letrozole and gonadotropins in women with estrogen-dependent cancers.

Authors:  Sung Woo Kim; Soo Jin Han; Ji Yeon Han; Hoon Kim; Seung-Yup Ku; Chang Suk Suh
Journal:  PLoS One       Date:  2020-10-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.